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thyroid gland, parotids and bone marrow according to and FLT ((18)F-
fluoro-thymidine)-PET images, before and during the treatment.  
Materials and Methods: Patients with advanced, inoperable 
oropharynx and oral cavity cancer were treated with chemoradiation. 
(RTCT). The dose of 70 Gy in 35 fractions was delivered concurrently 
with three courses of cisplatin(100mg/m2) provided on the 1st, 22nd 
and 43rd day of treatment. FLT PET/CT was performed a week before 
and then on 7th and 14th day of treatment, corresponding to a dose of 
14 and 28 Gy respectively. The whole imaging was performed while 
ensuring the same mode of patient’s immobilization i.e. individual 
thermoplastic mask. Volumes of thyroid gland, both parotids and 
cervical vertebrae were measured on CT scans obtained before 
treatment and at the FLT PET time point. CT and PET images were 
matched to assess the level of proliferation at the organ of interest. 
SUV mean was used to quantify differences in proliferation level. 
Thyroid hormones level were assayed prior to the treatment and then, 
weekly during the treatment followed by the one month after 
completion of the treatment evaluation to assess the level of 
functional changes. For statistical calculation Pearson’s correlation 
coefficient and Wilcoxon Matched Pair Test were used, for alpha=0.5  
Results: Both volume and FLT SUVmean of the thyroid gland 
decreased during treatment (p= 0.009 and 0.03 respectively). Changes 
of volume of thyroid gland correlated with the decrease of FLT 
SUVmean in the first week of treatment. (R=0.90) Thyroid hormones 
levels fluctuate during and after chemoradiation. Thyroid-stimulating 
hormone (TSH) level measured a month after RTCT negatively 
correlates with FLT SUVmean in the first week of treatment (R=0.89) 
Volume of homolateral and contralateral parotids decreases 
significantly during first week of treatment (p=0.003 and 0.01 
respectively). Degree of parotid volume change depends on its initial 
volume before treatment (R=0.7). FLT SUVmean reduction in bone 
marrow after first week of treatment reflects depletion of 
proliferating cells (p=0.002) 
Conclusions: Morphologica land functional changes in head and neck 
organs can be estimate during RTCT. Assessment of the volumetric 
and metabolic changes of certain organ at risk during treatment could 
be a predictor of their future function and can help in further 
individualization of treatment planning.  
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Purpose/Objective: Besides basic measurements as SUVmax, SUVmean or 
tumor volume derived from 18F-FDG PET scans, more advanced 
quantitative imaging features are increasingly investigated for 
treatment monitoring and outcome prediction. This is within the 
context of Radiomics: extracting and mining a large number of 
quantitative features from medical images, where it is hypothesized 
that it will improve tumor characterization and outcome prediction. 
However, in order to use these features for future prognostic and 
predictive models, it is required that they are reliable. This study 
therefore aims to assess the repeatability of Radiomics features 
derived from PET images in NSCLC. 
Materials and Methods: Eleven NSCLC patients were included 
retrospectively in this study. All patients underwent two baseline 18F-
FDG PET scans within a one day interval, before any treatment was 
delivered. 60-min. emission scans were obtained on an ECAT EXACT 
HR+ scanner (Siemens/CTI) in 2D mode and reconstructed using 
OSEM2Dx16s, followed by 5mm FWHM Gaussian post-smoothing. Per 
patient, all lesions with adequate uptake and contrast were identified 
and delineated by applying one of four predefined thresholds of the 
maximum uptake value within the tumor (41%, 50% and 70% corrected 
for local background and 50% uncorrected for background) (figure 1). 
The extracted image features comprised 15 first-order statistics, 33 
textural features derived from gray level co-occurrence and gray level 
run-length matrices, 51 metabolic descriptors of the intensity volume 
histogram (IVH) and 7 features describing the shape and size of the 
delineated VOI. Repeatability for every extracted image feature was 
assessed with the intraclass correlation (ICC) and the coefficient of 
repeatability (COR), expressed as a percentage of the sample 
estimated reference range. 
 
 
Results: 32 lesions were selected for analysis. Repeatability analysis 
of shape and size characteristics of the defined VOIs revealed a good 
agreement between the two baseline scans, with ICC and COR values 
ranging from 0.94-1 and 2.8%-17.1% respectively for all 7 features. 
13/15 of the considered first order statistics showed high repeatability 
with an ICC between 0.77–0.96 and a COR between 12.3%-38.6%. An 
ICC between 0.7-1 and a COR of 3.6%-37.2% was found for 28/33 
textural features. From the IVH features, 40/51 were highly 
repeatable with an ICC and a COR of 0.78-1 and 2.8%-31.4% 
respectively. The overall results are summarized in table 1. 
 
  
Conclusions: The results of this study indicate that the majority of 
assessed PET image features are highly repeatable and suggest that 
further analysis of these parameters may be warranted for treatment 
monitoring and outcome prediction in NSCLC. 
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Purpose/Objective: To test the hypothesis that cardiac comorbidity 
before the start of (chemo)radiotherapy (RCHT) is associated with an 
increased risk of radiation induced lung toxicity (RILT) in lung cancer 
patients. 
Materials and Methods: A prospective cohort of 149 non-resectable 
lung cancer patients with locoregional disease was studied, that was 
treated with definite (chemo)radiotherapy between 2007 and 2011 
(ClinicalTrials.gov Identifiers: NCT00572325 and NCT00573040). Prior 
to oncological therapy, 42 (28.2%) patients had recorded treatment of 
cardiovascular pathologies at a cardiology department and 44 (29.5%) 
developed RILT, measured by dyspnea grade ≥ 2 according to CTCv.3.0 
within 6 months after radiotherapy. 
Results: Half of the patients with cardiac comorbidity (21/42) 
presented with dyspnea grade ≥ 2 within 6 months after RCHT, 
compared to 21.5% (23/107) of those without such comorbidity. The 
odds ratio of RILT for a patient with a cardiac comorbidity was 3.65 
(p-value < 0.001, 95% CI: 1.70 – 7.81, see Figure 1). Conversely, for 
common factors associated with RILT, such as mean lung dose, age, 
smoking status, World Health Organization performance status and 
Forced Expiratory Volume in 1 second no significant associations were 
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found (odds ratios of 1.02, 1.019, 1.70, 1.04, 0.99 with p-values 0.79, 
0.3, 0.21, 0.88, 0.25 respectively in univariate analysis). We tested 
also whether our hypothesis is confirmed for the subset of patients 
with pre-treatment dyspnea grade 0 or 1, 124 (83.2%) patients, as high 
levels of dyspnea may well be due to congestive heart failure 
irrespective of RCHT. The results show an even higher odds ratio, 4.33 
(p-value < 0.001, 95% CI: 1.76-10.67), of maximal dyspnea ≥ 2 for 
patients with cardiac comorbidity. 
Figure 1. Frequency of RILT (measured by a CTCv3.0 dyspnea score 
within 6 months from the beginning of RCHT), for patients 
with/without cardiac comorbidity. The hypothesis that the odds ratio 
for post-RCHT dyspnea grade >=2 for the cardiac vs. no-cardiac 
comorbidity patients is equal to 1 is rejected (odds ratio = 3.65, p-
value <0.001, 95% CI = 1.70-7.81), total number patients = 149. 
 
 
Conclusions: Our results suggest that cardiac comorbidity is an 
important candidate factor for developing RILT after definite 
(chemo)radiotherapy of lung cancer patients. Therefore this 
observation should be further researched and externally validated.  
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Purpose/Objective: Chemoradiotherapy (CRT) represents an actual 
treatment standard in limited disease small cell lung cancer (LD SCLC) 
and timing of thoracic irradiation (TRT) has been already the subject 
of randomised trials and meta-analyses. Several of them reported 
significantly improved overall survival (OS) when platinum-based early 
concurrent CRT is used. To investigate a correlation between CRT 
schedule and OS a temporal analysis of the multimodality treatment 
was performed in patients with LD SCLC. 
Materials and Methods: 182 patients with PS WHO 0-3 who 
successfully completed CRT were retrospectively reviewed. Thoracic 
radiation therapy (TRT) was applied in the concurrent or sequential 
mode. Influence of the treatment mode and interval of simultaneous 
treatment (IST) (IST – an interval in days when chemotherapy and TRT 
were applied simultaneously, including also time between 
chemotherapy cycles) on OS was analysed. 
Results: 70 (38%) patients were treated with concurrent and 112 (61%) 
with sequential CRT. Median survival (MS) for the entire cohort was 
536 days (95% CI: 462 – 609) without difference between the groups 
(concurrent 599 vs. sequential 532 days, p = 0.9, log-rank test). IST 
was 0 in 112 (61%) patients treated with sequential CRT whereas in 
the concurrent CRT group 29 (16%) and 42 (23%) patients showed an 
IST < 35 and >35, respectively. Patients with IST < 35 demonstrated a 
trend to better OS (MS: IST 0 vs. >35 vs. <35 was 533 vs. 448 vs. 1169 
days, p = 0.109, log-rank test). When patients treated with sequential 
CRT were excluded from the analysis, statistical difference in OS 
achieved significance (p = 0.021, log-rank test). In the multivariate 
analysis of patients treated with concurrent CRT, IST < 35 remained 
be significant variable correlating with better OS (p = 0.039, Cox 
regression). 
Conclusions: Temporal analysis of CRT schedule revealed that IST < 35 
can represent an important treatment-related parameter correlating 
with OS in patients with LD SCLC. By exceeding this interval we have 
seen no further improvement of OS due to concurrent application of 
the multimodality treatment. 
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Purpose/Objective: Delineation of the gross tumour volume (GTV) in 
esophageal cancer remains difficult. Moreover, to compensate for 
microscopic tumour spread, the current standard is to use relatively 
large margins (3-4 cm) from GTV to clinical target volume (CTV). The 
aim of this study was: (1) to analyse the accuracy of GTV delineation; 
(2) to analyse if the margins to the CTV were sufficient at pathologic 
examination after neo-adjuvant chemoradiotherapy (neo-CHRT), and: 
(3) to investigate if pathological findings after neo-CHRT influenced 
overall survival (OS).  
Materials and Methods: The study population was composed of 63 
esophageal cancer patients treated with neo-CHRT. In all patients, 
planning-CT scans were used combined with all diagnostic information 
to determine the GTV and CTV. During surgery, the GTV and CTV 
borders, as delineated on the planning-CT scans, were demarcated in 
situ at the esophagus in order to provide information regarding the 
exact location of macroscopic and microscopic tumour (see Figure). 
Demarcation points consisted of anatomical reference points that 
could be easily recognised both at CT and intraoperative (e.g. 
tracheal bifurcation, aortic arch, celiac trunk). To identify prognostic 
factors for OS, univariate and multivariate analysis were performed. 
Results: After resection, macroscopic residual tumour was found 
outside the GTV in 7 patients (11%). Microscopic residual tumour was 
located outside the CTV in nine patients (14%), in most cases caudally 
from the CTV. Three of these patients had an R1-resection, including 
2 with circumferential invasion and only 1 with invasion of the cranial 
and caudal borders. Six patients were partial responders, while three 
showed almost no response. The median follow up was 16.6 months 
(95% CI 14-19 months). In the univariate analysis, microscopic tumour 
extension outside the CTV, ypN+, lymphangio-invasion, perineural 
growth, lymph node ratio >0.10 and >5 positive lymph nodes were 
associated with worse OS. In the multivariate analysis, only 
microscopic tumour extension outside the CTV (HR 4.96, 95%CI 1.03-
15.36) and perineural growth (HR 5.77, 95%CI 1.27-26.13) were 
identified as independent adverse prognostic for OS. Without tumour 
outside the CTV the 1 year OS was 86% vs. 20% for patients with 
tumour outside the CTV (p=<0.01). 
Conclusions: Despite using advanced pre-RT imaging and neo-CHRT, 
(1) macroscopic tumour outside the GTV was found in 11% of the 
patients and (2) microscopic tumour foci outside the CTV in 14% of the 
cases (mainly caudally from the CTV). (3) Moreover, the presence of 
microscopic tumour spread beyond CTV borders had a significant and 
major adverse impact on OS. These findings emphasize the 
importance of accurate delineation of the GTV and indicate that 
currently used margins from GTV to CTV in particular in caudal 
direction are not sufficient which may adversely impact treatment 
outcome.  
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Purpose/Objective: The main weakness of the radiotherapy workflow 
is undoubtly the GTV delineation. It is therefore important to validate 
automated segmentation methods in 2D but even better in 3D. FDG 
uptake within a tumor, assessed with PET-imaging, can be used to 
automatically create a tumor contour using standardized uptake value 
(SUV) thresholding. It has already been shown that the tumor length 
measured in the surgical specimen correlates highly with a PET-based 
autocontour. The goal of this study was to validate the volume of an 
automatic generated PET-based tumor contour with pathology for 
rectal cancer. 
Materials and Methods: Eight patients diagnosed with non-locally 
advanced rectal cancer (NLARC), referred for pre-operative treatment 
